Skip to main content
Key Specialties
Cardiology Diabetology Endocrinology Gastroenterology Geriatrics and Gerontology Gynecology and Obstetrics Hematology Infectious Disease Internal Medicine Nephrology Neurology Oncology Pediatrics Respiratory Medicine Rheumatology Surgery
Congress Coverage
2024 ACC Congress 2023 ESMO Congress 2023 EASD Congress 2023 ERS Congress 2023 ESC Congress
Clinical Collections
Advances in Alzheimer’s

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.
ADVANCED SEARCH
Log in
Top
Breast Cancer Research
Published in: Breast Cancer Research 4/2010

01-12-2010 | Short communication

The emerging breast cancer epidemic: early diagnosis and treatment

Author: Anthony Howell

Published in: Breast Cancer Research | Special Issue 4/2010

Login to get access

Excerpt

Breast cancer is the most common malignant tumour in women. Estimates for 2008 indicate that 1.38 million women were diagnosed and 0.46 million died from the disease worldwide [1]. Currently, the incidence in the developed and developing world is similar but, whereas incidence rates are tending to plateau or decline in the West, they are increasing in the developing world, presumably related to changes in dietary and reproductive behaviours and ageing populations [1]. Total mortality from breast cancer is already higher in the developing world [1]. Whilst mortality is declining in most western countries, it is estimated that it will increase by over 100% in developing countries by 2020 [2]. …
Literature
1.
Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM: Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer. 2010
2.
Rastogi T, Hildesheim A, Sinha R: Opportunities for cancer epidemiology in developing countries. Nat Rev Cancer. 2004, 4: 909-917. 10.1038/nrc1475.CrossRefPubMed
3.
Igene H: Global health inequalities and breast cancer: an impending public health problem for developing countries. Breast J. 2008, 14: 428-434. 10.1111/j.1524-4741.2008.00618.x.CrossRefPubMed
4.
Berry DA, Cronin KA, Plevritis S, Fryback DG, Clarke L, Zelen M, Mandelblatt JS, Yakovlev AY, Habbema JD, Feuer EJ: Effect of screening and adjuvant therapy on mortality from breast cancer. N Engl J Med. 2005, 353: 1784-1792. 10.1056/NEJMoa050518.CrossRefPubMed
5.
Kalager M, Haldorsen T, Bretthauer M, Hoff G, Thoresen SO, Adami HO: Improved breast cancer survival following introduction of an organised mammography screening program among both screened and unscreened women: a population-based cohort study. Breast Cancer Res. 2009, 11: R44-10.1186/bcr2331.CrossRefPubMedPubMedCentral
6.
Blanks RG, Moss SM, McGahan CE, Quinn MJ, Babb PJ: Effect of NHS breast screening programme on mortality from breast cancer in England and Wales, 1990-8: comparison of observed with predicted mortality. BMJ. 2000, 321: 665-669. 10.1136/bmj.321.7262.665.CrossRefPubMedPubMedCentral
7.
Thomas DB, Gao DL, Ray RM, Wang WW, Allison CJ, Chen FL, Porter P, Hu YW, Zhao GL, Pan LD, Li W, Wu C, Coriaty Z, Evans I, Lin MG, Stalsberg H, Self SG: Randomised trial of breast self-examination in Shanghai: final results. J Natl Cancer Inst. 2002, 94: 1445-1457.CrossRefPubMed
8.
Yip CH, Smith RA, Anderson BO, Miller AB, Thomas DB, Ang ES, Caffarella RS, Corbex M, Kreps GL, McTiernan A: Guideline implementation for breast healthcare in low and middle income countries: early detection resource allocation. Cancer. 2008, 113: 2244-2256. 10.1002/cncr.23842.CrossRefPubMed
9.
10.
Barton MB, Frommer M, Shafiq J: Role of radiotherapy in cancer control in low-income and middle-income countries. Lancet Oncol. 2006, 7: 584-595. 10.1016/S1470-2045(06)70759-8.CrossRefPubMed
11.
Bese NS, Munshi A, Budrukkar A, Elzawawy A, Pervez CA: Breast radiation therapy guideline implementation in low and middle income countries. Cancer. 2008, 113: 2305-2314. 10.1002/cncr.23838.CrossRefPubMed
12.
Eniu A, Carlson RW, El Saghir NS, Bines J, Bese NS, Vorobiof D, Masettie R, Anderson BO: Guideline implementation for breast healthcare in low and middle income countries: treatment resource allocation. Cancer. 2008, 113: 2269-2281. 10.1002/cncr.23843.CrossRefPubMed
13.
Mendis S, Fukino K, Cameron A, Laing A, Fillipe A, Khatib O, Leowski J, Ewen M: The availability and affordability of selected essential medicines for chronic diseases in six low and middle income countries. Bull World Health Organ. 2007, 85: 279-288. 10.2471/BLT.06.033647.CrossRefPubMedPubMedCentral
14.
Steinbrook R: Closing the affordability gap for drugs in low income countries. N Engl J Med. 2007, 357: 1996-1999. 10.1056/NEJMp0706918.CrossRefPubMed
15.
Wong NS, Anderson BO, Khoo KS, Ang PT, Yip CH, Lu YS, Shao ZM, Pritchard KI: Management of HER2-positive breast cancer in Asia: consensus statement from Asian Oncology Summit 2009. Lancet Oncol. 2009, 10: 1077-1085. 10.1016/S1470-2045(09)70230-X.CrossRefPubMed
16.
Bines J, Eniu A: Effective but cost-prohibitive drugs in breast cancer treatment: a clinician's perspective. Cancer. 2008, 113: 2353-2358. 10.1002/cncr.23837.CrossRefPubMed
17.
Badwe RA, Hawaldar RW, Parmar V, Nadkarni M, Shet T, Desai S, Gupta S, Rakesh J, Vanmali V: Single injection depot progesterone prior to surgery and survival in women with operable breast cancer: a randomised controlled trial. Cancer Res. 2009, 69 (24 Suppl): 72-10.1158/0008-5472.SABCS-09-72.CrossRef
18.
Cuzick J, Dowsett M, Wale C, Salter J, Quinn E, Zabaglo L, Howell A, Buzdar A, Forbes JF: Prognostic value of a combined ER, PgR, Ki67, HER2 immunohistochemical (IHC4) score and comparison with the GHI recurrence score - results from TransATAC. Cancer Res. 2009, 69 (24 Suppl): 74-10.1158/0008-5472.SABCS-09-74.CrossRef
19.
Love RR, Duc NB, Allred DC, Binh NC, Kha NN, Thuan TV, Mohsin SK, Roanh le D, Khang HX, Tran TL, Quy TT, Thuy NV, The PN, Cau TT, Tung ND, Huong DT, Quang le M, Hien NN, Thuong L, Shen TZ, Xin Y, Zhang Q, Havighurst TC, Yang YF, Hillner BE, DeMets DL: Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002, 20: 2559-2566. 10.1200/JCO.2002.08.169.CrossRefPubMed
20.
Ohno S, Rai Y, Iwata H, Yamamoto N, Yoshida M, Iwase H, Masuda N, Nakamura S, Taniguchi H, Kamigaki S, Noguchi S: Three dose regimens of fulvestrant in postmenopausal Japanese women with advanced breast cancer: results from a double-blind, phase II comparative study (FINDER1). Ann Oncol. 2010
21.
Pritchard KI, Rolski J, Papai Z, Mauriac L, Cardoso F, Chang J, Panasci L, Ianuli C, Kahan Z, Fukase K, Lindermann JP, Macpherson MP, Neven P: Results of a phase II study comparing three dosing regimens of fulvestrant in postmenopausal women with advanced breast cancer (FINDER2). Breast Cancer Res Treat. 2010
22.
Ragaz J, Wong H: Comparative analysis of breast cancer (BrCa) mortality reduction among regions of Canada between 1950-2004: impact of systemic and diagnostic guidelines after 1977 with a model definition of number of potentially avoided annual deaths (N-PAAD). Cancer Res. 2009, 69 (24 Suppl): 2063-10.1158/0008-5472.SABCS-09-2063.CrossRef
Metadata
Title
The emerging breast cancer epidemic: early diagnosis and treatment
Author
Anthony Howell
Publication date
01-12-2010
Publisher
BioMed Central
Published in
Breast Cancer Research / Issue Special Issue 4/2010
Electronic ISSN: 1465-542X
DOI
https://doi.org/10.1186/bcr2739

Other articles of this Special Issue 4/2010

Breast Cancer Research 4/2010 Go to the issue

Short communication

Contribution of biomarkers to personalized medicine

Short communication

Deciding priorities in Pharma

Short communication

Angiogenesis - still a worthwhile target for breast cancer therapy?

Section introduction

Introduction: are current drug development programmes realising the full potential of new agents?

Short communication

Molecular profiling contributes more than routine histology and immonohistochemistry to breast cancer diagnostics

Short communication

Emerging breast cancer epidemic: evidence from Africa
Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras
Prof. Fabrice Barlesi
Developed by: Springer Medicine
Image Credits